Abstract
Lowering low density lipoprotein (LDL) - cholesterol is one of the key issues in modern preventive cardiology by which we are able to interact with the natural course of atherosclerosis. Diet and healthy life style are mandatory for the treatment of CAD high risk patients. Numerous lipid lowering trials confirmed the beneficial effect of statins in primary as well as secondary prevention. By this statins are the basic treatment in patients with coronary artery disease (CAD) or diabetes mellitus or both. In order to reach LDL - cholesterol target levels (LDL - cholesterol < 100 mg/dl) in patients with CAD the use of potent statins or a lipid lowering combination therapy might be necessary. In our days we are able to lower LDL-cholesterol by more than 50% with drug treatment, which should enable us to reach the optimal LDL-cholesterol level in most patients.
Keywords: Lipid lowering therapy, atherosclerosis, coronary artery disease, prevention, cardiology, diabetes mellitus, atherogenic, overwhelming, revascularisation,, Lipidhypothesis, hyperlipidemia, simvastatin, Myopathic, rhabdomyolysis, cyclosporine, macrolide, digoxin, rosuvastatin, Ezetimibe
Current Pharmaceutical Design
Title: Lipid Management for the Prevention of Cardiovascular Disease
Volume: 17 Issue: 9
Author(s): Juergen R. Schaefer
Affiliation:
Keywords: Lipid lowering therapy, atherosclerosis, coronary artery disease, prevention, cardiology, diabetes mellitus, atherogenic, overwhelming, revascularisation,, Lipidhypothesis, hyperlipidemia, simvastatin, Myopathic, rhabdomyolysis, cyclosporine, macrolide, digoxin, rosuvastatin, Ezetimibe
Abstract: Lowering low density lipoprotein (LDL) - cholesterol is one of the key issues in modern preventive cardiology by which we are able to interact with the natural course of atherosclerosis. Diet and healthy life style are mandatory for the treatment of CAD high risk patients. Numerous lipid lowering trials confirmed the beneficial effect of statins in primary as well as secondary prevention. By this statins are the basic treatment in patients with coronary artery disease (CAD) or diabetes mellitus or both. In order to reach LDL - cholesterol target levels (LDL - cholesterol < 100 mg/dl) in patients with CAD the use of potent statins or a lipid lowering combination therapy might be necessary. In our days we are able to lower LDL-cholesterol by more than 50% with drug treatment, which should enable us to reach the optimal LDL-cholesterol level in most patients.
Export Options
About this article
Cite this article as:
R. Schaefer Juergen, Lipid Management for the Prevention of Cardiovascular Disease, Current Pharmaceutical Design 2011; 17 (9) . https://dx.doi.org/10.2174/138161211795428849
DOI https://dx.doi.org/10.2174/138161211795428849 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunotherapy in Liver Diseases: A Balance Between Immunity and Tolerance
Current Drug Metabolism Antioxidant Activity, α-glucosidase Inhibitory Activity and Chemoprotective Properties of Rhododendron brachycarpum Leaves Extracts
Current Pharmaceutical Biotechnology Metabolic Syndrome During Menopause
Current Vascular Pharmacology Editorial
Current Hypertension Reviews Glycogen Phosphorylase as a Target for Type 2 Diabetes: Synthetic, Biochemical, Structural and Computational Evaluation of Novel N-acyl-N´-(<i>β</i>-D-glucopyranosyl) Urea Inhibitors
Current Topics in Medicinal Chemistry Compounds that Combine Aldose Reductase Inhibitory Activity and Ability to Prevent the Glycation (Glucation and/or Fructation) of Proteins as Putative Pharmacotherapeutic Agents
Drug Design Reviews - Online (Discontinued) Aldose Reductase in the Retina
Current Enzyme Inhibition Patent Selections
Recent Patents on Cardiovascular Drug Discovery Emerging Evidence for the Role of Neurotransmitters in the Modulation of T Cell Responses to Cognate Ligands
Central Nervous System Agents in Medicinal Chemistry Sex Steroids Effects in Normal Endocrine Pancreatic Function and Diabetes
Current Topics in Medicinal Chemistry Cellular Cholesterol Efflux Pathways: Impact on Intracellular Lipid Trafficking and Methodological Considerations
Current Pharmaceutical Biotechnology Diabetic Medications in Pregnancy
Current Diabetes Reviews A Brief Review of circRNA Biogenesis, Detection, and Function
Current Genomics MicroRNAs in Diabetic β Cell Dysfunction and their Role as Biomarkers
Current Signal Transduction Therapy Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Pharmacokinetic Changes of Drugs in Rat Model of Acute Renal Failure Induced by Uranyl Nitrate: Correlation Between Drug Metabolism and Hepatic Microsomal Cytochrome P450 Isozymes
Current Clinical Pharmacology Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics
Mini-Reviews in Medicinal Chemistry Expression and Purification of Optimized rolGLP-1, A Novel GLP-1 Analog, in Escherichia Coli BL21(DE3) and its Good Glucoregulatory Effect on Type 2 Diabetic Mice
Current Pharmaceutical Biotechnology Identification of Phenolic Compounds from Nettle as New Candidate Inhibitors of Main Enzymes Responsible on Type-II Diabetes
Current Drug Discovery Technologies